Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis
Top Cited Papers
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 26 (9), 1105-1113
- https://doi.org/10.1097/qad.0b013e3283536a93
Abstract
Background: Interferon-gamma (IFNγ) is of key importance in the immune response to Cryptococcus neoformans. Mortality related to cryptococcal meningitis remains high, and novel treatment strategies are needed. We performed a randomized controlled trial to determine whether addition of IFNγ to standard therapy increased the rate of clearance of cryptococcal infection in HIV-associated cryptococcal meningitis. Methods: Patients were randomized to amphotericin B 1 mg/kg per day and 5FC 100 mg/kg per day for 2 weeks (standard therapy), standard therapy and IFNγ1b 100 μg days 1 and 3 (IFNγ two doses), or standard therapy and IFNγ1b 100 μg days 1, 3, 5, 8, 10 and 12 (IFNγ six doses). Primary outcome was rate of clearance of cryptococcus from the cerebrospinal fluid (CSF) (early fungicidal activity, EFA) calculated from serial quantitative cultures, previously shown to be independently associated with survival. Results: Rate of fungal clearance was significantly faster in IFNγ containing groups than with standard treatment. Mean EFA [log colony forming unit (CFU)/ml per day] was −0.49 with standard treatment, −0.64 with IFNγ two doses, and −0.64 with IFNγ six doses. Difference in EFA was −0.15 [confidence interval (95% CI) −0.02 to −0.27, P = 0.02] between standard treatment and IFNγ two doses, and −0.15 (95% CI −0.05 to −0.26, P = 0.006) between standard treatment and IFNγ six doses. Mortality was 16% (14/88) at 2 weeks and 31% (27/87) at 10 weeks, with no significant difference between groups. All treatments were well tolerated. Conclusion: Addition of short-course IFNγ to standard treatment significantly increased the rate of clearance of cryptococcal infection from the CSF, and was not associated with any increase in adverse events. Two doses of IFNγ are as effective as six doses.Keywords
This publication has 29 references indexed in Scilit:
- Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South AfricaJournal of Infection, 2010
- Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programmeAIDS, 2010
- Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected casesBMC Infectious Diseases, 2010
- Pulmonary Infection with an Interferon-γ-Producing Cryptococcus neoformans Strain Results in Classical Macrophage Activation and ProtectionThe American Journal of Pathology, 2010
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 PatientsClinical Infectious Diseases, 2009
- Cytokine Signaling Regulates the Outcome of Intracellular Macrophage Parasitism byCryptococcus neoformansInfection and Immunity, 2009
- High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll outAIDS, 2009
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Protection against Cryptococcosis by Using a Murine Gamma Interferon-ProducingCryptococcus neoformansStrainInfection and Immunity, 2007